Acuta Capital Partners’s Orchestra BioMed OBIO Stock Holding History

Acuta Capital Partners’s Portfolio OBIO Stock Details OBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-392,500	Closed	-$3.91M	–	52
2022 Q2	$3.91M	Hold	392,500	–	–	2.18%	16
2022 Q1	$3.89M	Hold	392,500	–	–	1.82%	19
2021 Q4	$3.96M	Hold	392,500	–	–	1.66%	22
2021 Q3	$3.88M	Hold	392,500	–	–	1.37%	22
2021 Q2	$4M	Hold	392,500	–	–	1.6%	22
2021 Q1	$4.39M	Hold	392,500	–	–	1.58%	29
2020 Q4	$5.03M	Hold	392,500	–	–	1.37%	28
2020 Q3	$4.32M	Buy	+392,500	New	+$4.41M	1.17%	29

Other funds holding OBIO

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

Acuta Capital Partners's OBIO Position: Q3 2022 in Review

Acuta Capital Partners sold out of Orchestra BioMed (OBIO) in Q3 2022, closing a stake of 392,500 shares — an estimated $3.91M sold.

Acuta Capital Partners first reported a position in OBIO in Q3 2020 and held it in 8 quarters. The position peaked at $5.03M in Q4 2020. 23 funds tracked by Wall St. Rank hold OBIO as of Q3 2022.

Acuta Capital Partners reported no remaining Orchestra BioMed position as of Q3 2022 after selling out during the quarter.
Acuta Capital Partners sold 392,500 Orchestra BioMed shares in Q3 2022, an estimated $3.91M.
Acuta Capital Partners first reported a position in Orchestra BioMed in Q3 2020 and held it in 8 quarters.
Acuta Capital Partners's Orchestra BioMed position peaked at $5.03M in Q4 2020.
23 funds tracked by Wall St. Rank held Orchestra BioMed as of Q3 2022.

Based on Acuta Capital Partners's 13F filing for Q3 2022, filed 14 Nov 2022.